Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Multi-center study to evaluate the impact of HIV-specific T-cell vaccines and Vorinostat compared to ART alone in patients with primary HIV infection

Trial Profile

Randomised, Multi-center study to evaluate the impact of HIV-specific T-cell vaccines and Vorinostat compared to ART alone in patients with primary HIV infection

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV vaccine (Primary) ; MVA HIV vaccine (Primary) ; Vorinostat (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms RIVER
  • Most Recent Events

    • 07 Mar 2019 Results of a RIVER GUT substudy (n=11) presented at the 26th Conference on Retroviruses and Opportunistic Infections
    • 28 Aug 2018 New trial record
    • 27 Jul 2018 Primary endpoint ((log10 total HIV-DNA copies/million from CD4+ T-cells at weeks PR-16&18)) has not been met, according to the results presented at the 22nd International AIDS Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top